Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Trial Profile

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms RUXO-BEAT; RuxoBEAT

Most Recent Events

  • 12 Dec 2023 Pre-specified interim Results (n=78) presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 01 Feb 2023 Results of pre-specified futility analysis assessing the early clinical benefit and tolerability of Ruxolitinib in previously untreated PV patients , published in the Annals of Hematology
  • 13 Dec 2022 Interim results (n=95) of pre-specified analysis reporting efficacy and safety data of ET patients presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top